Safety, pharmacokinetics, and pharmacodynamic activity of ABI-6250, a first in class oral hepatitis D virus entry inhibitor in healthy subjects: interim results from a randomized, blinded, phase 1a study

Hepcludex (bulevirtide-gmod) - Gilead

ABI-6250 - Assembly Biosci, Gilead

https://events-distribution.easl.eu/from.storage?image=X9WvFraREucXDOc3lNmAYGFMmaxq7mR2n1kvmXwreGz9NVnxgjwMdofVnROjRWc-0

Edward J. Gane1; Christian Schwabe2; Grace Wang3; Jieming Liu3; Nuruddin Unchwaniwala3; Jinghu Carl Li3; Steven J Knox3; Anuj Gaggar3; Katie Zomorodi3

Mar 18, 2026